[go: up one dir, main page]

MX337991B - Metodo para detectar cancer. - Google Patents

Metodo para detectar cancer.

Info

Publication number
MX337991B
MX337991B MX2013011525A MX2013011525A MX337991B MX 337991 B MX337991 B MX 337991B MX 2013011525 A MX2013011525 A MX 2013011525A MX 2013011525 A MX2013011525 A MX 2013011525A MX 337991 B MX337991 B MX 337991B
Authority
MX
Mexico
Prior art keywords
protein
cancer detection
caprin
fragment
detection method
Prior art date
Application number
MX2013011525A
Other languages
English (en)
Inventor
Fumiyoshi Okano
Kana Suzuki
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX337991B publication Critical patent/MX337991B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a un método in vitro para detectar cáncer, caracterizado porque comprende medir la expresión de un polipéptido que tiene una reactividad de unión por medio de una reacción antígeno-anticuerpo a un anticuerpo contra una proteína CAPRIN-1que tiene cualquiera de las secuencias de aminoácidos que se muestran en las SEC ID. NOS: 2 a 30 con numeración par en el listado de secuencias, sobre una superficie de célula cancerosa en una muestra separada de un organismo vivo. El método in vitro porque comprende detectar además el progreso de cáncer un base a un indicador de que la extensión del cáncer ha avanzado cuando el nivel de expresión del polipéptido es mayor que la de un control.
MX2013011525A 2008-08-05 2009-08-05 Metodo para detectar cancer. MX337991B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008202320 2008-08-05
PCT/JP2009/063883 WO2010016527A1 (ja) 2008-08-05 2009-08-05 癌の検出方法

Publications (1)

Publication Number Publication Date
MX337991B true MX337991B (es) 2016-03-30

Family

ID=41663744

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011001445A MX2011001445A (es) 2008-08-05 2009-08-05 Metodo para detectar cancer.
MX2013011525A MX337991B (es) 2008-08-05 2009-08-05 Metodo para detectar cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011001445A MX2011001445A (es) 2008-08-05 2009-08-05 Metodo para detectar cancer.

Country Status (16)

Country Link
US (1) US11137401B2 (es)
EP (2) EP2733492B1 (es)
JP (2) JP5644110B2 (es)
KR (2) KR20160039295A (es)
CN (1) CN102171570B (es)
AU (2) AU2009278387B2 (es)
BR (1) BRPI0911925B8 (es)
CA (1) CA2732980C (es)
DK (2) DK2325648T3 (es)
ES (2) ES2570731T3 (es)
HU (1) HUE027332T2 (es)
MX (2) MX2011001445A (es)
PL (2) PL2733492T3 (es)
PT (1) PT2325648E (es)
RU (2) RU2519089C2 (es)
WO (1) WO2010016527A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011001445A (es) 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
JP5691172B2 (ja) 2008-08-05 2015-04-01 東レ株式会社 癌の治療及び予防用医薬組成物
CN102844048A (zh) * 2010-02-04 2012-12-26 东丽株式会社 用于癌的治疗和/或预防的药物
JP5742713B2 (ja) 2010-02-04 2015-07-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CA2788547C (en) 2010-02-04 2018-06-05 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
RU2607366C2 (ru) 2010-02-04 2017-01-10 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
ES2540858T3 (es) * 2010-02-04 2015-07-14 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención de cáncer
ES2583777T3 (es) 2010-02-04 2016-09-22 Toray Industries, Inc. Composición farmacéutica que comprende anticuerpos anti CAPRIN-1 para el tratamiento y/o la prevención del cáncer
RU2611197C2 (ru) * 2011-08-04 2017-02-21 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
RU2595400C2 (ru) * 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
HUE047006T2 (hu) * 2011-08-04 2020-04-28 Toray Industries Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére
US9409993B2 (en) 2011-08-04 2016-08-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
ES2629061T3 (es) * 2011-08-04 2017-08-07 Toray Industries, Inc. Método para la detección de cáncer pancreático
CA2844040C (en) * 2011-08-04 2019-05-07 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
US9181334B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
BR112014021102A2 (pt) * 2012-02-21 2021-12-28 Toray Industries Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
CA2864864C (en) * 2012-02-21 2020-05-12 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
ES2749672T3 (es) * 2012-02-21 2020-03-23 Toray Industries Composición farmacéutica para tratar y/o prevenir el cáncer
MX360211B (es) * 2012-02-21 2018-10-24 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CN104203281B (zh) * 2012-03-30 2019-07-26 东丽株式会社 胆囊癌的治疗和/或预防用药物组合物
KR102155531B1 (ko) * 2012-03-30 2020-09-15 도레이 카부시키가이샤 간암의 치료 및/또는 예방용 의약 조성물
MX357292B (es) 2012-07-19 2018-07-04 Toray Industries Método para detectar cáncer.
WO2014014086A1 (ja) 2012-07-19 2014-01-23 東レ株式会社 癌の検出方法
PT3031826T (pt) 2013-08-09 2019-01-18 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro
WO2016084912A1 (ja) * 2014-11-27 2016-06-02 公立大学法人横浜市立大学 卵巣明細胞腺癌の検査方法及び検査薬
RU2611896C1 (ru) * 2016-03-10 2017-03-01 Федеральное государственное бюджетное учреждение здравоохранения Клиническая больница N 122 имени Л.Г. Соколова Федерального медико-биологического агентства (ФГБУЗ КБ N 122 им. Л.Г. Соколова ФМБА России) Способ диагностики лейомиомы мочевого пузыря
TWI782000B (zh) * 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
US20210107989A1 (en) * 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
RU2677064C1 (ru) * 2017-10-13 2019-01-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ определения границ резекции при лечении остеосаркомы
JP6875451B2 (ja) * 2018-09-26 2021-05-26 株式会社レナテック 犬のがんリスク評価方法及びがんリスク評価システム
WO2020067261A1 (ja) * 2018-09-26 2020-04-02 株式会社レナテック 犬のがんリスク評価方法及びがんリスク評価システム

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
RU2161042C2 (ru) 1994-09-19 2000-12-27 Дж. Моро Рикардо Обнаружение и лечение рака
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US20030118599A1 (en) * 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
HUP0203035A3 (en) 1998-07-14 2007-12-28 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
EP1187915A2 (en) 1999-04-02 2002-03-20 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
ES2418360T3 (es) 1999-04-09 2013-08-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU1438001A (en) 1999-10-29 2001-05-14 Human Genome Sciences, Inc. 27 human secreted proteins
JP2004526401A (ja) * 2000-03-29 2004-09-02 コリクサ コーポレイション 肺癌の治療および診断のための組成物および方法
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040029114A1 (en) * 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
AU2002311909A1 (en) * 2001-05-11 2002-11-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
IL159894A0 (en) 2001-07-17 2004-06-20 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins
RU2319709C2 (ru) 2001-07-17 2008-03-20 Рисерч Дивелопмент Фаундейшн Терапевтические агенты, содержащие проапоптозные белки
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
JP3869352B2 (ja) 2002-11-12 2007-01-17 日鉱金属株式会社 金属箔の熱量測定方法、表面特性の調整方法、レーザー穴開け方法又は熱量測定装置
EP2179742A1 (en) 2002-11-26 2010-04-28 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) * 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
CA2524173A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
CA2553826A1 (en) 2004-01-26 2005-12-08 Debiovision Inc. Neoplasm-specific polypeptides and their uses
CA2560305C (en) 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) * 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
SI1839662T1 (sl) 2005-01-19 2010-07-30 Zeria Pharm Co Ltd Antitumorsko sredstvo
KR20150083139A (ko) 2005-01-21 2015-07-16 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
US7858324B2 (en) 2005-02-18 2010-12-28 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
MX2007011024A (es) 2005-03-11 2009-11-23 Vermillion Inc Biomarcadores para cancer de ovario y cancer de endometrio: hepcidin.
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
CA2635616A1 (en) 2006-01-05 2007-07-19 Carlo M. Croce Microrna expression abnormalities in pancreatic endocrine and acinar tumors
EP1991701A4 (en) 2006-02-14 2010-03-17 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING, AND TREATING CANCER
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008031041A2 (en) * 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP4958580B2 (ja) 2007-02-21 2012-06-20 鹿島建設株式会社 シールド機、シールド機とセグメントの間のクリアランス測定方法
EP3106873B1 (en) 2007-10-25 2019-07-17 Toray Industries, Inc. Method for detection of cancer
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
ES2629067T3 (es) 2008-03-18 2017-08-07 Genentech, Inc. Combinaciones de un conjugado de anticuerpo anti-HER2-fármaco y pertuzumab
MX2011001445A (es) 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
JP5691172B2 (ja) 2008-08-05 2015-04-01 東レ株式会社 癌の治療及び予防用医薬組成物
ES2619322T3 (es) 2008-08-05 2017-06-26 Toray Industries, Inc. Agente inductor de inmunidad
EP2467401B1 (en) 2009-08-19 2017-01-18 Merck Patent GmbH Antibodies for the detection of integrin complexes in ffpe material
US8642292B2 (en) 2009-09-22 2014-02-04 Probiogen Ag Process for producing molecules containing specialized glycan structures
ES2583777T3 (es) 2010-02-04 2016-09-22 Toray Industries, Inc. Composición farmacéutica que comprende anticuerpos anti CAPRIN-1 para el tratamiento y/o la prevención del cáncer
RU2607366C2 (ru) 2010-02-04 2017-01-10 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
ES2540858T3 (es) 2010-02-04 2015-07-14 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención de cáncer
JP5742713B2 (ja) 2010-02-04 2015-07-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CA2788547C (en) 2010-02-04 2018-06-05 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CN102844048A (zh) 2010-02-04 2012-12-26 东丽株式会社 用于癌的治疗和/或预防的药物
KR101271964B1 (ko) 2010-07-08 2013-06-07 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
NZ606195A (en) 2010-07-26 2015-02-27 Servier Lab Methods and compositions for liver cancer therapy
US9181334B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
US9409993B2 (en) 2011-08-04 2016-08-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
RU2611197C2 (ru) 2011-08-04 2017-02-21 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
HUE047006T2 (hu) 2011-08-04 2020-04-28 Toray Industries Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére
CA2844040C (en) 2011-08-04 2019-05-07 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
ES2629061T3 (es) 2011-08-04 2017-08-07 Toray Industries, Inc. Método para la detección de cáncer pancreático
CA2864864C (en) 2012-02-21 2020-05-12 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112014021102A2 (pt) 2012-02-21 2021-12-28 Toray Industries Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
MX360211B (es) 2012-02-21 2018-10-24 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
ES2749672T3 (es) 2012-02-21 2020-03-23 Toray Industries Composición farmacéutica para tratar y/o prevenir el cáncer
CN104203281B (zh) 2012-03-30 2019-07-26 东丽株式会社 胆囊癌的治疗和/或预防用药物组合物
KR102155531B1 (ko) 2012-03-30 2020-09-15 도레이 카부시키가이샤 간암의 치료 및/또는 예방용 의약 조성물
WO2014014086A1 (ja) 2012-07-19 2014-01-23 東レ株式会社 癌の検出方法
MX357292B (es) 2012-07-19 2018-07-04 Toray Industries Método para detectar cáncer.
PT3031826T (pt) 2013-08-09 2019-01-18 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro

Also Published As

Publication number Publication date
DK2325648T3 (da) 2014-07-28
BRPI0911925B8 (pt) 2024-02-06
KR20110052665A (ko) 2011-05-18
BRPI0911925B1 (pt) 2024-01-30
PL2325648T3 (pl) 2014-09-30
PT2325648E (pt) 2014-06-24
JP5825386B2 (ja) 2015-12-02
EP2325648A1 (en) 2011-05-25
JPWO2010016527A1 (ja) 2012-01-26
AU2015238877A1 (en) 2015-10-29
AU2009278387A1 (en) 2010-02-11
BRPI0911925A2 (pt) 2016-09-20
US11137401B2 (en) 2021-10-05
MX2011001445A (es) 2011-04-05
EP2733492B1 (en) 2016-02-24
RU2014111182A (ru) 2015-09-27
DK2733492T3 (en) 2016-04-25
HUE027332T2 (en) 2016-09-28
ES2471379T3 (es) 2014-06-26
EP2325648A4 (en) 2011-09-28
RU2011108258A (ru) 2012-09-10
JP5644110B2 (ja) 2014-12-24
CA2732980C (en) 2017-08-15
AU2015238877B2 (en) 2017-02-16
RU2519089C2 (ru) 2014-06-10
KR20160039295A (ko) 2016-04-08
CN102171570A (zh) 2011-08-31
KR101606779B1 (ko) 2016-03-28
EP2733492A1 (en) 2014-05-21
ES2570731T3 (es) 2016-05-20
RU2671497C2 (ru) 2018-11-01
WO2010016527A1 (ja) 2010-02-11
EP2325648B1 (en) 2014-04-23
PL2733492T3 (pl) 2016-08-31
CN102171570B (zh) 2014-10-15
AU2009278387B2 (en) 2015-07-09
CA2732980A1 (en) 2010-02-11
JP2014134550A (ja) 2014-07-24
US20110136121A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
MX337991B (es) Metodo para detectar cancer.
CA2844033C (en) Method for detecting pancreatic cancer
NZ603492A (en) Humanized anti-factor d antibodies and uses thereof
AU2006246342B2 (en) Melanoma-associated endogenous retrovirus (MERV) derived peptide sequences and their therapeutic/ diagnostic use
MX345316B (es) Métodos y composiciones para diagnóstico y tratamiento del cáncer.
NZ597692A (en) Anti-IGF antibodies
HK1089232A1 (en) Use of a midregional proadrenomedullin partial peptide in biological fluids in the production of immological diagnostic agents
MX358772B (es) Metodo para detectar cancer.
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
HK1097855A1 (en) Method of detecting probnp with a monoclonal antibody binding to the amino acid 41-46
MX2015000686A (es) Metodo para detectar cancer.
WO2008012362A3 (en) New protein isoforms and uses thereof
WO2010045495A3 (en) Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
ATE535546T1 (de) Humane monoklonale antikörper, die spezifisch an ifg-ii binden
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
RU2022108606A (ru) Антитела к фактору ix padua
UA101142C2 (ru) Способ разработки антитела
WO2007112054A3 (en) Facilitation of translocation of molecules through the gastrointestinal tract
WO2008136510A1 (ja) 自己免疫性膵炎及び劇症１型糖尿病の検査方法及び検査試薬
WO2009090269A8 (en) Markers and diagnostic methods for metastasis
RU2013118454A (ru) Антитело к эфрину в2 и его применение
WO2009125318A3 (en) Selective enrichment of n-terminally modified peptides from complex samples
WO2006089801A3 (de) Verfahren zum redox-potential-abhängigen nachweis von targetmolekülen durch wechselwirkende polypeptide
RU2014114532A (ru) Способ измерения антитела против wt1